NCT07720102

Brief Summary

This study evaluates satisfaction with percutaneous ablation and any symptoms experienced before and after the procedure in patients with lung tumors.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
28mo left

Started Sep 2026

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 17, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 22, 2026

Completed
1 month until next milestone

Study Start

First participant enrolled

September 1, 2026

Expected
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2028

5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2028

Last Updated

July 22, 2026

Status Verified

July 1, 2026

Enrollment Period

1.9 years

First QC Date

July 17, 2026

Last Update Submit

July 17, 2026

Conditions

Lung Neoplasm

Outcome Measures

Primary Outcomes (1)

  • Symptom severity following percutaneous lung ablation

    Assessed using a study-specific survey. Participants evaluate 5 symptoms (pain, fatigue, drowsiness, shortness of breath, and disturbed sleep), each on an 11-point Likert scale of 0-10 where 0=absence of symptoms and 10=as bas as you can imagine. Higher scores indicate greater severity of symptoms.

    Baseline (prior to ablation), 1 day, 3 days, 7 days, 1 month, 3 months

Study Arms (1)

Observational

Patients complete surveys throughout the study.

Other: Non-Interventional Study

Interventions

Non-Interventional StudyOTHER

Non-interventional study

Also known as: Non-Interventional Observational Study, Noninterventional (Observational) Study
Observational

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patients undergoing percutaneous lung ablation recruited from Mayo Clinic in Rochester

You may qualify if:

  • Undergoing percutaneous lung ablation

You may not qualify if:

  • Decline to participate in research

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

Location

Related Links

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Ahmad Parvinian, MD

    Mayo Clinic in Rochester

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Clinical Trials Referral Office

CONTACT

855-776-0015mayocliniccancerstudies@mayo.edu

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 17, 2026

First Posted

July 22, 2026

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

July 31, 2028

Study Completion (Estimated)

December 31, 2028

Last Updated

July 22, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will not share

Locations

US(1)